Back to User profile » Dr Jonathan Marshall
Papers published by Dr Jonathan Marshall:
Response to the Letter to the Editor by Zambelli et al for In Silico Lung Deposition Profiles of Three Single-Inhaler Triple Therapies in Patients With COPD Using Functional Respiratory Imaging [Response To Letter]
Singh D, Roche N, Wu L, Sadafi H, De Backer J, Monshi Tousi N, Marshall J
International Journal of Chronic Obstructive Pulmonary Disease 2026, 21:597524
Published Date: 3 March 2026
In Silico Lung Deposition Profiles of Three Single-Inhaler Triple Therapies in Patients with COPD Using Functional Respiratory Imaging
Singh D, Roche N, Wu L, Sadafi H, De Backer J, Monshi Tousi N, Marshall J
International Journal of Chronic Obstructive Pulmonary Disease 2025, 20:2103-2116
Published Date: 27 June 2025
Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS
Muro S, Seki M, Hurst JR, Petullo D, Marshall J, Bowen K, Darken PF, Duncan EA, Megally A, Patel M
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:2729-2737
Published Date: 12 December 2024
Temporal Dynamics of Cardiovascular Risk in Patients with Chronic Obstructive Pulmonary Disease During Stable Disease and Exacerbations: Review of the Mechanisms and Implications
Simons SO, Heptinstall AB, Marjenberg Z, Marshall J, Mullerova H, Rogliani P, Nordon C, Hawkins NM
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:2259-2271
Published Date: 10 October 2024
Budesonide/Glycopyrrolate/Formoterol for the Management of COPD in a UK Primary Care Population: Real-World Use and Early Medication Success
Müllerová H, Chan JSK, Heatley H, Carter V, Townend J, Skinner D, Franzén S, Marshall J, Price D
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:1153-1166
Published Date: 24 May 2024
CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients
Alves L, Pullen R, Hurst JR, Miravitlles M, Carter V, Chen R, Couper A, Dransfield M, Evans A, Hardjojo A, Jones D, Jones R, Kerr M, Kostikas K, Marshall J, Martinez F, Melle MV, Murray R, Muro S, Nordon C, Pollack M, Price C, Sharma A, Singh D, Winders T, Price DB
Patient Related Outcome Measures 2022, 13:53-68
Published Date: 23 February 2022